OrphAI Therapeutics
Guilford
About OrphAI Therapeutics
AI Therapeutics was founded in 2013 with a mission to advance the clinical development of new therapies to treat Lymphangioleiomyomatosis (LAM) and other diseases. Working with a dedicated team of scientific, clinical, and drug development experts, AI Therapeutics expects to use its disease-specific focus and technological approach to identify and advance drugs that will provide significant therapeutic benefits for LAM patients. AI Therapeutics develops drugs for rare diseases and cancer. LAM takes advantage of the inflection point in biological understanding and computer science, leveraging big data from NextGen sequencing, genome editing, chemical genomics, and combinational drug screening, to develop precision therapeutics and companion diagnostics. LAM has advanced two drugs into the clinic: LAM-001 for lymphangioleiomyomatosis, and LAM-002 for B-cell non-Hodgkin lymphoma.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Estimated revenue: $1K – $10K
- Total funding: $98.0M
- Funding stage: Late Stage Venture
- Last round: Series C (Mar 2017)
- Website: ai-therapeutics.com
- Phone: (203)458-7100
Industries & Categories
Artificial Intelligence (AI), Biotechnology, Genetics, Medical, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/orphai-therapeutics-11392 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.